Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.

Conclusions: TCZ infusion add-on is highly efficacious and well-tolerated in Korean patients with active RA refractory to conventional DMARDs including MTX. EULAR good response at week 12 could predict DAS28 remission at week 72.
PMID: 29334721 [PubMed - as supplied by publisher]

Source: The Korean Journal of Internal Medicine - January 17, 2018 Category: Internal Medicine Authors: Baek HJ, Lim MJ, Park W, Park SH, Shim SC, Yoo DH, Kim HA, Lee SK, Lee YJ, Park YE, Cha HS, Song YW Tags: Korean J Intern Med Source Type: research